Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
BioCina Has Been Awarded Grants to Develop mRNA Vaccines
BioCina, a leading contract development and manufacturing organization (CDMO) is pleased to announce that it […]
Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
Arix Bioscience, a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces […]
Vertex Announces FDA Approval for TRIKAFTA in Children With Cystic Fibrosis
Vertex Pharmaceuticals has announced the U.S. Food and Drug Administration (FDA) approved the expanded use […]
Direct Biologics Receives FDA Clearance to Initiate Phase 1b/2a Clinical Trial of ExoFlo™ in Patients with Medically Refractory Perianal Fistulizing Crohn’s Disease
Direct Biologics, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) […]
BioAge Labs to Present on Therapeutics for Brain Aging Targeting NLRP3, Apelin, and Other Novel Pathways
BioAge Labs, a privately held clinical-stage biotechnology company developing therapeutics that target the molecular causes […]
Ultromics Granted FDA Breakthrough Device Designation for AI-Enhanced Cardiac Amyloidosis Detection
Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been […]
Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder
Sunovion Pharmaceuticals and Otsuka Pharmaceutical Development & Commercialization today announced that the first patient has […]
Bridgewest Perth Pharma to Commercialize Sterile Injectable Drugs Under LumaCina Business Unit
Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, […]
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
Xencor, a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer […]
Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more